AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases. Founded by David R. Elmaleh in 2011, AZTherapies is backed by investors that include Cosine, DRADS Capital, IBS Capital, Spinnaker Capital, and Wexford Capital and is headquartered in Boston.